# Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

> **NCT05494697** · PHASE2 · SUSPENDED · sponsor: **AIM ImmunoTech Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Rintatolimod

## Key facts

- **NCT ID:** NCT05494697
- **Lead sponsor:** AIM ImmunoTech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-06
- **Primary completion:** 2029-12
- **Final completion:** 2030-01
- **Target enrollment:** 90 (ESTIMATED)
- **Why stopped:** A business decision to place screening/enrollment on hold. Study redesign/amendment pending additional Ampligen-related data from an ongoing Phase I-II open label study (NCT05927142)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05494697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05494697, "Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05494697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*